The congress' contributors

Carin A. Uyl-de Groot (1966) is Professor of Health Technology Assessment at Erasmus University Rotterdam and director of the Institute for Medical Technology Assessment (iMTA b.v.). Since 2014, she has been a member of the Dutch Committee on Expensive Cancer Drugs (CieBOM) and, since 2015, of the Dutch Health Council.

Her research focuses on cost-effectiveness and outcomes studies, with patient perspectives consistently integrated as a crucial element. She is principal investigator for disease registries and international projects, including ASCERTAIN under Horizon Europe and NIH-supported initiatives, ensuring that patient-reported outcomes are part of the evidence base guiding healthcare decisions.

Uyl-de Groot supervises numerous PhD students and contributes as editor and reviewer to several leading journals. Her work has been published in Lancet Oncology, Nature Reviews Clinical Oncology, Journal of Clinical Oncology, JAMA, BMJ, and Blood, and presented at major international conferences. Her influential papers, including a novel drug pricing model in Nature Reviews and an analysis of disparities in access to cancer drugs in Cancers, have received wide recognition. Across all projects, she emphasizes that meaningful evaluation of healthcare innovations requires not only clinical and economic evidence but also the inclusion of patient voices.